Significant Agreements (Tables)

12 Months Ended

Dec. 31, 2023

Neurocrine Collaborative Agreement 2023

Schedule of allocation of variable consideration

Performance Obligation	Amount
	(in thousands)
Variable Consideration
GBA1 Program	$	5,920
2023 Discovery Program 1		3,779
2023 Discovery Program 2		780
2023 Discovery Program 3		780
Total	$	11,259

Schedule of allocation of fixed consideration

Performance Obligation	Amount
	(in thousands)
Fixed Consideration
GBA1 Program	$	69,459
2023 Discovery Program 1		24,807
2023 Discovery Program 2		24,807
2023 Discovery Program 3		24,807
Total	$	143,880

Neurocrine Collaborative Agreement 2019

Schedule of allocation of variable consideration

Performance Obligation	Amount
	(in thousands)
Variable Consideration
VY-AADC Program	$	53,863
FA Program		20,309
2019 Discovery Program 1		4,286
2019 Discovery Program 2		4,793
Total	$	83,251

Schedule of allocation of fixed consideration

Performance Obligation	Amount
	(in thousands)
Fixed Consideration
VY-AADC Program	$	49,045
FA Program		20,647
2019 Discovery Program 1		14,443
2019 Discovery Program 2		8,247
Total	$	92,382

Neurocrine collaborative Agreement 2023 and Neurocrine Collaborative Agreement 2019

Schedule of collaboration receivables and contract liabilities

	Balance at						Balance at
	December 31, 2022		Additions		Deductions		December 31, 2023
		(in thousands)
Related party collaboration receivable	$	257	$	10,081	$	(6,997)	$	3,341
Contract liabilities:
Deferred revenue	$	11,827	$	74,420	$	(11,007)	$	75,240